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Arrestins were identified as mediators of G protein-coupled receptor (GPCR) desensitization and endocy-
tosis. However, it is now clear that they scaffold many intracellular signaling networks to modulate the
strength and duration of signaling by diverse types of receptors—including those relevant to the Hedgehog,
Wnt, Notch, and TGFb pathways—and downstream kinases such as the MAPK and Akt/PI3K cascades. The
involvement of arrestins in many discrete developmental signaling events suggests an indispensable role for
these multifaceted molecular scaffolds.Introduction
Across development and phylogeny, a relatively small number
of core signaling pathways are consistently reutilized for the
patterning, growth, differentiation, and homeostasis of embry-
onic and adult tissues. In recent years, multifunctional adaptor
proteins known as arrestins have come to be appreciated as
important mediators of many of these pathways, including the
Hedgehog (Hh), Wingless, Notch, and TGFb pathways. The
arrestins constitute a small family of gene products that were
originally discovered as molecules that desensitize, or turn off,
classical G protein-coupled receptor (GPCR) signaling. Upon
ligand binding, GPCRs undergo conformational changes that
allow them to be recognized by the family of GPCR kinases
(GRKs) that phosphorylate the receptors on their intracellular
loops and C-terminal tails (Premont and Gainetdinov, 2007). Ar-
restin binding to the receptors is generally enhanced by GRK-
mediated phosphorylation of multiple sites on the inner surface
of the receptors. This modification leads to b-arrestin recruit-
ment, which sterically interdicts further signaling to G proteins,
thus leading to the classical phenomenon of receptor desensiti-
zation. Arrestins can also mediate endocytosis of receptors,
leading to numerous physiological outcomes including receptor
degradation, receptor recycling, and the generation of ‘‘signalo-
somes’’ where arrestins scaffold various proteins to potentiate
distinct downstream signaling events.
There are four members of the arrestin family. Visual arrestin
(arrestin 1) is localized to retinal rods and cones, whereas X-ar-
restin (arrestin 4) is found exclusively in retinal cones. b-arrestins
1 and 2 (arrestins 2 and 3, respectively) are ubiquitously distrib-
uted. All of the proteins are closely related (70% sequence
identity) and the sequence similarity between the b-arrestins is
highly conserved across species (Gurevich and Gurevich,
2006). Arrestins contain N- and C-terminal domains consisting
almost entirely of antiparallel beta sheets. The two domains,
moreover, share a very similar fold despite the absence of anysequence similarity. This domain is known as an ‘‘arrestin
fold.’’ It should also be noted that despite a lack of extensive
conservation in primary amino acid sequence, Vps26 (which is
part of a retromer subcomplex involved in recognition of cargo
at the endosome and retrograde transport to the Golgi complex;
Collins et al., 2008) and mammalian arrestins appear to have
similar structures, and share not only the aforementioned
arrestin fold, but a polar core as well (Shi et al., 2006). It is
tempting to speculate that the arrestin fold is one of the structural
signatures for the regulation of membrane trafficking in the cell.
Over the past decade, evidence has emerged that the
b-arrestins play much wider roles in biology than previously
imagined. They serve as multifunctional adaptors and scaffolds
that mediate the clathrin-dependent endocytosis of diverse 7
transmembrane-spanning receptors (7TMRs, which include
classical GPCRs), subserve a growing list of signaling functions,
act as adaptors for various E3 ubiquitin ligases, and have many
other roles (Table 1). Thus, in addition to their originally discov-
ered role as desensitizers of G protein-mediated signaling, the
b-arrestins serve as signal transducers in their own right. As
shown in Table 1, the range of 7TMR-coupled signaling systems
that are engaged through the b-arrestins has grown rapidly, as
has the list of cellular processes that are regulated by these
b-arrestin-mediated pathways. Several recent reviews have
covered this very exciting, dynamic, and rapidly expanding field
of research (Defea, 2008; DeWire et al., 2007; Ma and Pei, 2007).
Recently, an even more surprising development has been the
growing list of publications that document roles for the b-arrest-
ins in signaling and/or endocytosis of noncanoncical families of
cellular receptors and transporters (Table 2). These include non-
receptor and receptor tyrosine kinases (RTKs), nonclassical
7TMRs like Smoothened (Smo) and Frizzled (Fz), ion channel
receptors, and cytokine receptors. As with the GPCRs, many
of these molecules interact with the b-arrestins in a ligand- or
stimulus-dependent fashion. Moreover, many of these newlyDevelopmental Cell 17, October 20, 2009 ª2009 Elsevier Inc. 443
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regulating cellular proliferation, differentiation, and apoptosis.
This rapidly growing area has received much less attention and
serves as the focus of this review.
b-arrestin Gene Knockouts
Considering the numerousways in which b-arrestins are involved
in the regulation and control of important receptors and signal-
ing molecules, it would seem likely that genetic ablation of
arrestins would have significant developmental consequences.
The Drosophila melanogaster genome encodes a single arrestin
gene, kurtz (krz), which is essential for development and survival
(Roman et al., 2000). Krz is ubiquitously expressed during early
embryogenesis and is later concentrated in the central nervous
system.Krz is also highly expressed in fat bodies, and krzmutants
form melanotic tumors due to the disaggregation of fat bodies
(Roman et al., 2000). The expression of Krz in the neuronal tissue
of fly larvae is essential for viability (Romanet al., 2000).Continued
research in Drosophila demonstrating that Krz is required for
receptor desensitization and olfactory sensitivity suggests that
many of the classical functions of arrestins are conserved
between multiple species (Ge et al., 2006; Johnson et al., 2008).
b-arrestin 1 knockout mice develop normally, but b-arrestin 1
is required for normal adrenergic response (Conner et al., 1997).
b-arrestin 2 knockout mice develop normally as well, but display
increased analgesia in response to morphine (Bohn et al., 1999)
due to misregulated internalization and desensitization of the
m-opiod receptor (Bohn et al., 2000). Over the past decade,
numerous examples of supersensitive or diminished 7TMR
signaling have been demonstrated in b-arrestin 1 or 2 knockout
mice (DeWire et al., 2007; Kohout and Lefkowitz, 2003). Even
with impaired signaling in numerous pathways, mice with either
b-arrestin 1 or b-arrestin 2 ablated appear healthy and function
normally unless challenged. However, unpublished studies indi-
cate that simultaneous ablation of both b-arrestins in mice leads
to multiple developmental abnormalities incompatible with post-
natal survival (C.L.D., J.J.K., J. Klingensmith, and R.J.L, unpub-
lished data). These phenotypes suggest that each b-arrestin
can functionally compensate for the other in the developing
mouse embryo. Indeed, in several receptor systems, b-arrestins
can perform interchangeable functions in signaling pathways
(DeWire et al., 2007).
Table 1. b-arrestin-Dependent Signaling Pathways Engaged by
GPCRs
GPCRs
b-arrestin-Dependent
Signaling Molecules Reference
AT1AR ERK, JNK3, Akt,
p90RSK, BAD,
FLNA, Mnk1,
eIF4E, RhoA
Ahn et al., 2009; Barnes
et al., 2005; DeWire et al.,
2008; Luttrell et al., 2001;
McDonald et al., 2000;
Scott et al., 2006
a2aAR ERK, c-Src Pierce et al., 2000;
Wang et al., 2006b
b1AR ERK, c-Src Kim et al., 2008b
b2AR ERK, c-Src, PDE,
Mdm2, Nedd4,
USP33, PIP5K,
IkBa, eNOS, p38
Gao et al., 2004; Li et al.,
2009; Luttrell et al., 1999;
Nelson et al., 2008; Ozawa
et al., 2008; Perry et al., 2002;
Shenoy et al., 2001, 2006,
2008, 2009; Gong et al., 2008
CXCR4 AIP4, ERK, p38 Bhandari et al., 2007;
Sun et al., 2002
CCR7 ERK Zidar et al., 2009
D1R ERK Chen et al., 2009a
D2R Akt, PP2A, GSK3b Beaulieu et al., 2008;
Beaulieu et al., 2005
FSH-R ERK Kara et al., 2006
GHS-R1a ERK, c-Src Camina et al., 2007
GLP-1R ERK, CREB Sonoda et al., 2008
GPR109A ERK Walters et al., 2009
5-HT2AR ERK Schmid et al., 2008
5-HT2CR ERK Labasque et al., 2008
LPAR ERK Iacovelli et al., 2002
M1R ERK, DGK, FLNA Nelson et al., 2007;
Scott et al., 2006
M3R ERK Luo et al., 2008
mGluR III ERK Jiang et al., 2006
MT1R ERK Bondi et al., 2008
dOR p300 Kang et al., 2005
kOR ERK, p38 Bruchas et al., 2006;
McLennan et al., 2008
mOR ERK Macey et al., 2006
OX1R ERK Milasta et al., 2005
P2Y2R ERK Hoffmann et al., 2008
PAFR p38 McLaughlin et al., 2006
PAR-1 PI3K, Akt Goel et al., 2002
PAR-2 ERK, PI3K, cofilin,
LIMK, chronophin
DeFea et al., 2000;
Wang and DeFea, 2006;
Zoudilova et al., 2007
PGE2R c-Src, Akt Buchanan et al., 2006
PTH1R ERK Gesty-Palmer et al., 2006
US28 p38 Miller et al., 2003
V2R ERK, c-Src Charest et al., 2007;
Ren et al., 2005
XGnRHR ERK Caunt et al., 2006
AT1AR, angiotensine type 1A receptor; a2aAR, a2a-adrenergic receptor;
b1(2)AR, b1(2)-adrenergic receptor; AIP4, atrophin-interacting protein 4;
DGK, diacylglycerol kinase; D1(2)R, D1(2) dopamine receptor; eNOS, endo-
thelial nitric oxide synthase; FLNA, filamin A; FSH-R, follicle-stimulating
hormone receptor; GHS-R1a, ghrelin receptor growth hormone secreta-
gogue receptor type 1a; GLP-1R, glucagon-like peptide-1 receptor;
5-HT2AR, serotonin 2A receptor; 5-HT 2C receptor, serotoinin 2C
receptor; JNK3, c-Jun N-terminal kinase 3; LIMK, LIM domain kinase;
LPAR, lysophosphatidic acid receptor; mGluR III, group III metabotropic
glutamate receptor; M1R, M1 muscarinic acetylcholine receptor; MT1R,
MT1 melatonin receptor; Mnk1, MAP kinase-interacting kinase 1;
Nedd4, neural precursor cell expressed, developmentally downregulated
4; OR, opioid receptor; OX1R, orexin 1 receptor; P2YR, purinergic
receptor; PAFR, platelet activating factor receptor; PAR-1, protease acti-
vated receptor-1; PDE, phosphodiesterase; PIP5K, phosphatidylinositol
4-phosphate 5-kinase; PGE2R, prostaglandin E2 receptor; PTH1R, type
I parathyroid hormone receptor; PP2A, protein phosphatase 2A; USP33,
ubiquitin specific peptidase 33; V2R, arginine vasopressin receptor 2;
XGnRHR, Xenopus gonadotropin-releasing hormone receptor.444 Developmental Cell 17, October 20, 2009 ª2009 Elsevier Inc.
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Smoothened
Smo is a member of the 7TMR family that controls activation of
the Hh signaling pathway. Modulation of Smo and its down-
stream signaling cascades may undergo species-specific regu-
lation (Huangfu and Anderson, 2006). Notably, the C-terminal
cytoplasmic tail of Smo differs significantly between species,
which may provide clues to differing mechanisms of regulation
and signal transduction (Varjosalo et al., 2006). In general, Smo
activity is repressed by the 12 membrane-spanning receptor
Patched (Ptc). Ptc acts as a receptor for the Hh family of ligands,
which are morphogens that regulate everything from Drosophila
larval segmentation to mammalian organogenesis and stem cell
maintenance (Ingham and McMahon, 2001; Jiang and Hui,
2008). Binding of Hh ligands to Ptc relieves its repression of
Smo, which allows activation of downstream signaling cascades
(Murone et al., 1999). Typical 7TMRs are known to associate and
signal through heterotrimeric G proteins, earning the name
GPCRs. After activation, these receptors interact with b-arrest-
ins in a ligand-dependent and usually phosphorylation-depen-
dent manner (Kohout and Lefkowitz, 2003; Zhang et al., 1997).
In the case of Smo, G protein coupling has been examined for
more than a decade, after an initial study implicating G protein
activity in zebrafish Hh signaling (Hammerschmidt and McMa-
hon, 1998). However, the involvement of G protein-mediated
signaling activity downstream of Smo has remained controver-
sial. Recently, a study has shown the necessity of Gai for proper
Hh signaling in Drosophila (Ogden et al., 2008). Additionally,
other GPCR-associated signaling proteins, the b-arrestins and
Table 2. Emerging b-arrestin-Coupled Receptors and Signaling
Events
Receptor
b-arrestin-Dependent
Signaling Activity Reference
Frizzled recruitment of Dsh,
endocytosis, activation
of b-catenin, convergent
extension movement
Bryja et al., 2007;
Bryja et al., 2008;
Chen et al., 2001;
Chen et al., 2003b;
Kim and Han, 2007;
Kim et al., 2008a
IGF1R endocytosis, ERK activation,
Mdm2-mediated receptor
ubiquitination, desensitization
Dalle et al., 2002;
Dalle et al., 2001;
Girnita et al., 2005;
Girnita et al., 2007;
Hupfeld et al., 2005;
Lin et al., 1998
Insulin
receptor
interaction with Akt and Src Luan et al., 2009
Notch ubiquitination of Notch Mukherjee et al., 2005
Smoothened internalization, translocation
to primary cilia, transcriptional
activation
Chen et al., 2004;
Kovacs et al., 2008;
Meloni et al., 2006;
Wilbanks et al., 2004
TbRIII internalization/endocytosis,
downregulation of Smad
and p38 signaling,
Cdc42 activation
Chen et al., 2003a;
Finger et al., 2008;
Mythreye and
Blobe, 2009
Endoglin ERK activation Lee and Blobe, 2007GRK-2, have been identified as important modulators of Hh
signaling, lending insight into the mechanisms of Smo regulation
(Figure 1).
In 2004, two studies revealed the importance of b-arrestin 2
and GRK-2 in the Hh pathway (Chen et al., 2004; Wilbanks
et al., 2004). One study showed that knocking down b-arrestin
2 protein levels in zebrafish embryos phenocopied Smomutants:
ventrally curved bodies, underdeveloped heads, partial cyclopia,
and loss of some midline tissues (resulting in characteristic
U-shaped somites) all indicate Hh pathway defects (Wilbanks
et al., 2004). Subsequent studies of zebrafish GRK-2 knockdown
obtained analogous results (Philipp et al., 2008). In mammalian
cells, Smo activation recruits b-arrestin 2 to the cell membrane
where it promotes endocytosis of Smo via clathrin-coated pits
through a GRK-2-dependent mechanism (Chen et al., 2004). In
fact, GRK-2 phosphorylates Smo, potentiating its interaction
with b-arrestin 2, and thus enhancing its signaling activity (Meloni
et al., 2006). Thus, in both zebrafish embryos and in mammalian
cell culture, b-arrestin 2 and GRK-2, key regulators of GPCRs,
also serve as key regulators of a nonclassical 7TMR, Smo.
However, b-arrestins are not only important mediators of
7TMR internalization and subcellular localization (Lefkowitz
andWhalen, 2004; Shenoy and Lefkowitz, 2003); they also serve
as scaffolding proteins that mediate distinct signaling and
subcellular trafficking events (Lefkowitz et al., 2006). Vertebrate
Smo translocates to primary cilia during pathway activation
(Corbit et al., 2005; Huangfu and Anderson, 2005), and this
translocation event is mediated by members of the intraflagellar
transport (IFT) complex (May et al., 2005), which are in turn
required for proper regulation of Hh signaling. The kinesin-2
motor complex, an anterograde molecular motor that transports
protein complexes to and within cilia and flagella (Hirokawa,
2000), is involved in Hh signaling (Huangfu et al., 2003). Specifi-
cally, one kinesin-2 subunit, Kif3A, has been shown to be
essential for Hh signaling in mammalian systems (Huangfu and
Anderson, 2006). Interestingly, b-arrestin was recently found to
bind Kif3A (Xiao et al., 2007) and localize to primary cilia (Kovacs
et al., 2008; Molla-Herman et al., 2008). In fact, both b-arrestin
1 and 2 are necessary for the formation of a ‘‘translocation
complex’’ between Smo and Kif3A that promotes activity-
dependent localization of Smo to primary cilia and activation of
downstream transcriptional targets in mammalian cells (Kovacs
et al., 2008), suggesting an intricate scaffolding mechanism that
regulates Hh signaling.
The association between b-arrestin and GRK-2 function in Hh
signaling and ciliary localization of Smo may provide important
insight into evolutionary differences between vertebrate and
invertebrate Hh signaling. While b-arrestins, GRK-2, and primary
cilia are important for Hh signal transduction in vertebrates,
these functions are not conserved across metazoans. Primary
cilia are rare in Drosophila, and the Drosophila arrestin, Krz,
has not been implicated in Hh signaling. The C-terminal region
of Smo that is phosphorylated by GRK-2 for b-arrestin recruit-
ment and signaling is divergent between vertebrates and inverte-
brates. In fact, the residues phosphorylated by GRK-2 are
absent from Drosophila Smo. A recent study has revealed that
Drosophila Smo is unable to translocate to primary cilia and
activate mammalian Hh pathway signaling in cultured Smo null
cells (Chen et al., 2009b). On the other hand, the same studyDevelopmental Cell 17, October 20, 2009 ª2009 Elsevier Inc. 445
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are evolutionarily conserved. Consequently, it appears that the
roles of the b-arrestins are divergent between species, and
may only be necessary for Smo function in vertebrate systems.
Supporting this idea, a study of zebrafish has shown that loss
of IFT ablates primary cilia and dampens Hh signaling in the
developing animal, though downstream transcriptional activities
do not appear to require primary cilia absolutely (Huang and
Schier, 2009). The fact that b-arrestins are required for localiza-
tion of Smo to primary cilia, combined with the data from these
studies, suggest that b-arrestinsmay function as upstream regu-
lators of the Hh pathway specifically in vertebrates.
It was recently shown that Smo regulates a noncanonical
Src-dependent pathway responsible for the mediation of axon
guidance (Yam et al., 2009). Perhaps b-arrestins serve as a link
between Smo and c-Src, as both have been identified as
b-arrestin interacting proteins (Luttrell et al., 1999). It will be inter-
esting to determine whether b-arrestins may regulate yet to be
identified noncanonical signaling events downstream of Smo.
Frizzled and Wingless
Wingless is the founding member of the Wnt family of secreted
glycoproteins that signal through a distinct family of 7TMRs
termed Fz receptors (Logan andNusse, 2004). TheWnts regulate
cell proliferation, differentiation, and polarity at various stages of
Figure 1. b-arrestins Mediate Vertebrate Hedgehog Signaling
(1) Upon Hh binding, Ptc-mediated repression of Smo is released, resulting in (2) phosphorylation of Smo by GRK-2 and formation of a complex between Smo,
b-arrestins, and themolecular motor Kif3A. (3) The Smo-b-arrestin-Kif3A complex translocates Smo to the primary ciliumwhere (4) Smo cleaves Gli into its active
form. (5) Active Gli then translocates down the primary cilium and (6) into the nucleus where it activates transcription of downstream targets.446 Developmental Cell 17, October 20, 2009 ª2009 Elsevier Inc.
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the Axin scaffold allows glycogen synthase kinase 3b (GSK3b) to
phosphorylate cytoplasmic b-catenin, inducing its degradation.
However, during so-called ‘‘canonical’’ Wnt signaling, Wnts
bind to Fz, Disheveled (Dsh) proteins are activated, and Axin/
GSK3b action on b-catenin is prevented. b-catenin, thus stabi-
lized, accumulates in the cytoplasm, and can translocate into
the nucleus, where it binds to TCF/LEF-transcription factors
and promotes transcriptional activation (Figure 2).
In noncanonical Wnt signaling, Fz activates two prominent
b-catenin-independent pathways. In theWnt/Planar Cell Polarity
(PCP) pathway, Wnts signal through Fz to the small GTPases,
Rho and Rac, to promote changes in the actin cytoskeleton
(Schlessinger et al., 2009) (Figure 2). In a second noncanonical
Wnt pathway, Wnts promote the release of intracellular calcium
and negatively regulate the canonical Wnt/b-catenin pathway
(Kohn and Moon, 2005).
b-arrestins have been implicated as important mediators of
both canonical and noncanonical Wnt signaling, but in different
capacities. It has been reported that heterotrimeric G proteins
couple to Fzs in both the canonical and noncanonical pathways
(Katanaev et al., 2005; Wang et al., 2006a), and, consequently, it
is not surprising that b-arrestins act downstream of these
receptors. b-arrestin 1 was initially found to interact with phos-
phorylated Dsh1 and Dsh2 (Chen et al., 2001), and in turn was
shown to synergistically enhance LEF-mediated transcriptional
activity when coexpressed ectopically with either Dsh1 or
Dsh2. b-arrestin 2 interacts with both Axin and Dsh after
Wnt3A stimulation of mouse embryo fibroblasts (MEFs) (Bryja
et al., 2007), thus suggesting that it has an essential role in scaf-
folding this critical interaction, resulting in inactivation of GSK3b
and subsequent stabilization of b-catenin (Figure 2). On the other
hand, during Wnt5A-stimulated noncanonical signaling, phos-
phorylated active Dsh2 binds b-arrestin 2 and recruits it to the
Figure 2. b-arrestins Are Involved in Both Canonical and Noncanonical Wnt Signaling
(1) In canonical Wnt signaling, in the absence of receptor stimulation, the Axin-APC complex degrades b-catenin and strongly represses transcriptional activity.
(2) Upon Wnt binding to Fz, b-arrestins bind to the receptor through Dsh, thus sequestering Axin and GSK3 away from b-catenin, (3) leading to its stabilization.
(4) b-arrestins also act to internalize Fzs into endosomeswhile (5) b-catenin is free to translocate into the nucleus and initiate transcription. (6) During noncanonical
Wnt signaling, b-arrestin complexes with Dsh and AP-2 after Wnt binding to Fz. (7) Subsequently, b-arrestin activates the GTPases RhoA and Rac1 leading to
(8) ROCK activation, (9) actin reorganization and convergent extension, or (10) JNK activation.Developmental Cell 17, October 20, 2009 ª2009 Elsevier Inc. 447
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cytosis of Fz4. b-arrestin 2 requires Dsh to interact with Fz for
internalization, unlike endocytosis of Smo, in which b-arrestin 2
binds to Smo directly. Interestingly, this is the only receptor
reported to recruit b-arrestin that requires an intermediary
binding partner. There is also evidence in other cellular contexts
that Wnt ligands can stimulate PI3K-mediated activation of Akt
(Kawasaki et al., 2007; Kim and Han, 2007) and/or ERK signaling
cascades (Kim et al., 2004; Yun et al., 2005). These signaling
molecules are well known to be regulated by b-arrestins (DeWire
et al., 2007) and may further support the notion that b-arrestins
play important roles in the activation of canonical and noncanon-
ical Wnt signaling.
The importance of b-arrestins for canonical and noncanonical
Wnt signaling in vivo has been demonstrated by a series of
studies in Xenopus. Morpholino-mediated b-arrestin 2 knock-
down in Xenopus embryos reduces b-catenin activation and
blocks Wnt8- or Dsh-induced axis duplication (Bryja et al.,
2007), indicating inhibition of the canonical Wnt signaling
pathway. b-arrestin 2 does not affect b-catenin-dependent
secondary axis differentiation, suggesting a requirement for
b-arrestin 2 in canonical Wnt signaling downstream of casein
kinase (CK) and Dsh, but upstream of b-catenin. b-arrestin 2 is
also required for convergent extension (CE) during Xenopus
axis elongation, a classical model of noncanonical Wnt/PCP
signaling. b-arrestin-2-deficient mesoderm fails to polarize and
intercalate with wild-type mesoderm at the midline (Kim et al.,
2008a). b-arrestin may collaborate with the PCP pathway to acti-
vate RhoA and regulate convergent extension movement
(Figure 2), supporting previous findings that b-arrestins are
required for RhoA activation in cell culture (Barnes et al., 2005).
In Xenopus CE, b-arrestin 2 works cooperatively with the RTK
Ryk tomediate the endocytosis of Fz7 and Dsh afterWnt11 stim-
ulation (Kim et al., 2008a). Subsequent studies have indicated
that this effect is mediated through activation of Rac1 (Bryja
et al., 2008). These data indicate that b-arrestins play crucial
roles in both canonical and noncanonical Wnt signaling, yet their
involvement ismost likely tightly regulatedwithin specific arms of
these pathways.
An intriguing link between the Wnt pathways and the b-arrest-
ins may be found at primary cilia, where both canonical and non-
canonical Wnt pathway members are enriched (Eggenschwiler
and Anderson, 2007). Indeed, b-arrestins are concentrated in
the primary cilia (Kovacs et al., 2008) and at the centrosome or
basal bodies of the cilia (Molla-Herman et al., 2008) as are other
Wnt signaling molecules such as Dsh (Park et al., 2008), APC,
b-catenin (Corbit et al., 2008), GSK3b (Thoma et al., 2007), and
Inversin (Watanabe et al., 2003). Primary cilia are required
in vivo for noncanonical (specifically PCP) Wnt signaling (Ross
et al., 2005). Conversely, the disassembly of primary cilia results
in increased levels of b-catenin activation and signaling (Cano
et al., 2004; Corbit et al., 2008; Lin et al., 2003). However, it
should be noted that recent studies suggest that primary cilia
are not required for canonical Wnt signaling in developing mice
or zebrafish (Huang and Schier, 2009; Ocbina et al., 2009).
Perhaps primary cilia or basal bodies act as microdomains
(Christensen et al., 2008) that facilitate regulation of specific
signaling intermediates, but that are not required for all aspects
and variations of a given signaling pathway. If so, it seems448 Developmental Cell 17, October 20, 2009 ª2009 Elsevier Inc.possible that b-arrestins in or near primary cilia and the centro-
somes would play a role in this unique microdomain-dependent
regulation of these Wnt subpathways.
The TGFb Superfamily and Cytokine Signaling
The transforming growth factor b (TGFb) superfamily contains
over 30 secreted proteins that include the TGFbs, bone morpho-
genic proteins (BMPs), growth and differentiation factors (GDFs),
activins, and several other members important for development
and homeostasis (Feng and Derynck, 2005; Gordon and Blobe,
2008). They are involved in numerous developmental processes
including gastrulation and germ-layer specification, axis forma-
tion, left-right asymmetry, patterning, and various stages of
organogenesis (Wu and Hill, 2009). The TGFb ligands signal
through type I and type II TGFb family serine/threonine kinase
receptors. The numerous permutations of type I receptor/type
II receptor/ligand combinations possible within the TGFb super-
family of ligands and receptors creates a remarkable diversity of
signaling outcomes (Feng and Derynck, 2005). Activated type I
receptors phosphorylate Smad transcriptional mediators,
promoting their accumulation in the nucleus where they bind
DNA and regulate gene transcription (Massague and Wotton,
2000). Smad-dependent mechanisms are the most widely
studied downstream mediators of TGFb signaling; however,
recent studies have also delineated several Smad-independent
signaling pathways downstream of TGFb superfamily receptors
(Zhang, 2009) involving a number of well characterized signaling
cascades including various mitogen activated protein kineases
(MAPKs), PI3K/Akt, and Rho-like GTPases. As b-arrestins have
been implicated in the regulation of all of these pathways
(DeWire et al., 2007), it may not be surprising that b-arrestin func-
tions extend beyond the 7TMR systems discussed above to
cytokine receptors, including those involved in TGFb signaling.
The type III TGFb receptor (TbRIII or betaglycan) is a corecep-
tor that contributes to TGFb signaling through mechanisms
that have yet to be fully understood. b-arrestin 2 binds TbRIII
(Chen et al., 2003a) and mediates its clathrin-independent/lipid
raft pathway-dependent internalization (Finger et al., 2008).
This b-arrestin-2-mediated internalization event downregulates
TGFb signaling, including both Smad phosphorylation and
Smad-independent p38 phosphorylation (Finger et al., 2008)
(Figure 3). Recent studies have shown that b-arrestin 2 also
mediates TbRIII-induced activation of Cdc42 (Mythreye and
Blobe, 2009) and inhibition of NF-kB-dependent cell migration
(You et al., 2009). The b-arrestin-2-dependent activation of
Cdc42 is reminiscent of b-arrestin-1-mediated activation of
Rho after stimulation of the Angiotensin Type 1A Receptor
(AT1AR) (Barnes et al., 2005) and requirements for b-arrestin
2 and p38 for pseudopodia extension and chemotaxis (Ge
et al., 2003; Hunton et al., 2005). In this context, it is interesting
to note the diversity of mechanisms by which TbRIII/b-arrestin
2 complexes influence TGFb superfamily signals. Whereas
b-arrestin-induced internalization attenuates TGFb signaling, it
potentiates signaling by the type I BMP receptor, ALK6. How-
ever, TbRIII acts in a b-arrestin-independent manner to retain
the closely related type I BMP receptor, ALK3, on the cell surface
(Lee et al., 2009).
The endothelial-specific TGFb receptor family member endo-
glin also interacts with b-arrestin 2, leading to its internalization
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TGFb-dependent ERK activation is b-arrestin 2 dependent
(Lee and Blobe, 2007). In fact, the b-arrestin 2/endoglin interac-
tion is responsible for sequestering ERK in the cytoplasm and
subsequently preventing cell migration without affecting Smad-
dependent signaling. Again, it appears that b-arrestins may be
involved in Smad-dependent and -independent signaling mech-
anisms downstream of TGFb receptors. While retention of ERK
in the cytoplasm by b-arrestins may attenuate certain ERK
signaling cascades in the nucleus, it has previously been shown
that cytosolic ERK has distinct substrates and functions from
nuclear ERK (Ahn et al., 2004; Tohgo et al., 2002). Consequently,
specific b-arrestin-mediated subcellular localization of ERK
downstream of TGFb receptors, and other b-arrestin-linked
receptors, may prove to be significant in multiple developmental
pathways.
Further evidence for the involvement of b-arrestins in cytokine
signaling comes from a series of studies involving the activation
of TGFb-activated kinase 1 (TAK1) by the E3 ligase tumor
necrosis factor receptor-associated factor 6 (TRAF6). TAK1 is
one of the activating MAP kinase kinase kinases that were orig-
inally found to be activated by TGFb signaling (Yamaguchi et al.,
1995). Later it was shown to be involved in BMP-dependent
mesoderm induction in Xenopus (Shibuya et al., 1998) and
proper formation of vasculature in developing mouse embryos
(Jadrich et al., 2006). TGFb treatment induces TRAF6 to polyubi-
quitinate itself and TAK1, resulting in p38/JNK pathway activa-
tion and apoptosis (Sorrentino et al., 2008; Yamashita et al.,
2008). Indeed, direct binding of TRAF6 to TGFb receptors is
required for apoptosis in murine hepatocytes and epithelial to
mesenchymal transition (EMT) in mouse mammary epithelial
cells (Yamashita et al., 2008). That said, the TRAF6/TAK1
complex mediates activation of JNK and NF-kB not only by
TGFb (Shim et al., 2005), but also by the Toll-like receptor-inter-
leukin 1 receptor (TLR-IL-1R) (Wang et al., 2006c). b-arrestin 2 is
necessary for the auto K63-linked polyubiquitination of TRAF6
in response to TLR-IL-1R stimulation (Wang et al., 2006c)
(Figure 4A). These studies raise the possibility that b-arrestin 2
may serve as an E3 ligase adaptor for TRAF6 toward TAK1,
and may serve to regulate diverse cytokine receptor pathways,
Figure 3. b-arrestins Regulate Multiple Aspects of TGFb Superfamily Signaling
(1) Upon ligand binding to the TbRI, -RII, and -RIII type receptors, (2) b-arrestin binds TbRIII (3) while TbRII phophorylates TbRI, which in turn activates R-Smads.
(4) Activated R-Smads complex with co-Smads and (5) translocate into the nucleus where they initiate transcription. (6) Meanwhile, b-arrestin internalizes TbRIII,
(7) thus attenuating TGFb-mediated activation of R-Smads. (8) Additionally, TbRIII is able to activate p38 in a Smad-independent manner after TGFb binding and
(9) b-arrestin-mediated internalization of TbRIII attenuates this signaling as well. (10) Downstream of TGFb-binding, b-arrestin is essential for the activation of
Cdc42, which is responsible for (11) actin reorganization leading to (12) chemotaxis and filipodial extension.Developmental Cell 17, October 20, 2009 ª2009 Elsevier Inc. 449
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ling ERK, JNK, p38 and TAK1.
The IGF-1 Receptor
The role of b-arrestins also extends to RTKs. The Insulin-like
growth factors (IGF-1 and IGF-2) are peptides that bind two
cell surface receptors (IGF1R and IGF2R) and signal through a
number of accessory proteins (Laviola et al., 2007). The IGF-1
receptor is a heterotetrameric protein with two transmembrane
domains whose cytoplasmic substituents act as tyrosine
kinases. IGF binding initiates signaling cascades that include
the PI3K/Akt and Ras/Raf/MEK/ERK pathways, which regulate
cell growth, survival, and differentiation (Siddle et al., 2001).
IGF signaling has been implicated in fetal growth and the growth
and maintenance of various organs, including but not limited to
the central nervous system, bone, skeletal muscle, and the
pancreas (Dupont and Holzenberger, 2003). Furthermore, aber-
rant IGF1R signaling has been shown to play important roles in
tumorigenesis (Chitnis et al., 2008).
b-arrestins were found to regulate the endocytosis and mito-
genic signaling of IGF1R more than a decade ago (Lin et al.,
1998). Much like a typical 7TMR, it was shown that b-arrestin 1
and b-arrestin 2 associated with IGF1R after ligand stimulation
and positively mediate ERK phosphorylation (Figure 4B). IGF1R
was later discovered to utilize both G proteins and b-arrestins
to mediate signaling in response to IGF-1 stimulation, even
though it is not a 7TMR (Dalle et al., 2001). IGF1R signaling is
dependent upon b-arrestin 1, whereas that by the closely related
insulin receptor (IR) is not. Intriguingly, it was recently found
that stimulation with insulin nonetheless initiates a signaling
Figure 4. b-arrestins Are Multifunctional Signaling Adaptors
(A) b-arrestin promotes the ubiquitination of TRAF6. (1) Upon binding of ligand to the Toll-like Receptor, b-arrestin binds to and promotes the autoubiquitination of
TRAF6. This autoubiquitination event is required for downstream activation of TAK and subsequent activation of NF-kB signaling. (2) It may be that b-arrestin-
mediated ubiquitination of TRAF6 leads to activation of TAK, which inhibits IKK, (3) thus freeing NF-kB from IKK-mediated inhibition. (4) This would then allow
NF-kB translocation into the nucleus and activation of transcription.
(B) b-arrestin acts as an E3 ligase adaptor in response to IGF stimulation. (1) After IGF binds to the tetrameric IGF1R, b-arrestin recruits Mdm2 to the receptor.
(2) Mdm2 ubiquitinates IGF1R, thus (3) leading to its internalization. (4) Once internalized, IGF1R is degraded by the protoesome, and (5) b-arrestin mediates the
activation of ERK from internalized ‘‘signalosomes.’’ (6) ERK then translocates to the nucleus and activates transcription.
(C) Krzmediates the ubiquitination and degradation ofDrosophilaNotch. (1) A Notch ligand on the Notch-ligand presenting cell bindsNotch. (2) This event triggers
the formation of a complex between Krz and the E3 ligase Dx. (3) Krz brings Dx to Notch and promotes Notch ubiquitination, (4) which leads to the Krz-dependent
internalization of Notch, and (5) its subsequent degradation.450 Developmental Cell 17, October 20, 2009 ª2009 Elsevier Inc.
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insulin sensitivity (Luan et al., 2009).
Though the mechanisms underlying the b-arrestin 2 interac-
tion with IR signaling have yet to be elucidated, the conse-
quences of formation of the IGF1R-b-arrestin 1 complex have
been more thoroughly examined. When b-arrestin 1 binds the
IGF1R, it recruits the E3 ubiquitin ligase Mdm2 to the receptor,
leading to its proteosomal degradation (Girnita et al., 2005).
Mdm2 also ubiquitinates b-arrestin 1 in a reversible fashion
(Girnita et al., 2007); a modification that has been shown to
regulate subcellular trafficking of several receptors and signalo-
somes (Shenoy and Lefkowitz, 2003). IGF1-induced Mdm2-
meditated ubiquitination of b-arrestin 1 promotes the intracel-
lular trafficking of b-arrestin 1 to signalosomes that mediate
ERK signaling by the IGF1R (Figure 4B), and, in turn, control
cell cycle progression even in the absence of RTK signaling
(Girnita et al., 2007). Interestingly, IGF stimulation enhances
the dephosphorylation of b-arrestin 1 (Hupfeld et al., 2005),
which results in an active form of b-arrestin 1 at the cell
membrane. This active b-arrestin 1 plays a direct role in desen-
sitizing IGF1R G protein-coupled signaling (Dalle et al., 2002).
This suggests that b-arrestin 1 modulates two separate signaling
arms from the IGF1R, similar to its regulation of many 7TMRs,
RTKs and ion channels (DeWire et al., 2007). The significant
involvement of the b-arrestins in IGF and Insulin-mediated
signaling pathways suggests that b-arrestins may be involved
in many other hormone-related developmental and homeostatic
signaling pathways.
Notch
Notch, a single transmembrane spanning receptor, was first
identified in flies and worms as a mediator of lateral inhibition,
controlling the allocation of cell fate and the balance between
cell proliferation and differentiation. These receptors are charac-
terized by EGF-like repeats in the extracellular domain. Misregu-
lation of the four mammalian Notch receptors has been impli-
cated in numerous diseases and developmental abnormalities
(Harper et al., 2003). Canonical Notch ligands are transmem-
brane proteins that bind Notch receptors and initiate juxtacrine
signaling via a complicated sequence of proteolytic cleavage
events culminating in g-secretase-dependent production of
a free Notch intracellular domain (NICD), which translocates
into the nucleus to serve as a transcriptional coregulator (Kopan
and Ilagan, 2009).
Interestingly, while there are four mammalian Notch receptors,
there is only one unique Notch in Drosophila melanogaster. That
singular Notch is regulated by the unique nonvisual arrestin
homolog Krz. In D. melanogaster one effect of ligand stimulation
is to recruit the E3 ligase Deltex (Dx) to associate with Notch
(Takeyama et al., 2003) and influence signaling (Matsuno et al.,
1995). However, the specific mechanism by which Dx mediated
Notch signaling remained unknown until it was shown that Notch,
Dx, and Krz form a complex, and that Krz promotes Dx E3 ligase
activity toward Notch, leading to its ubiquitination and degrada-
tion (Mukherjee et al., 2005) (Figure 4C), reminiscent of b-ar-
restin-mediated ubiquitination of other receptors. However, this
work begs the question of how Krz and Dx promote Notch
signaling, and whether this interaction may both positively and
negatively regulate Notch signaling. Furthermore, it will be inter-esting to investigate whether b-arrestins are also involved in
vertebrate Notch signaling.
b-arrestin-Dependent Pathways Converge on Common
Cytoplasmic Effectors
In recent years it has become evident that b-arrestins serve as
molecular scaffolds for a myriad of signaling proteins (DeWire
et al., 2007). It should come as no surprise that many of these
signaling molecules lie downstream of receptors such as Smo,
the Frzs, the TbRs, and many others. The proper functioning
and tight regulation of these cascades has been shown to be
essential for development of numerous organisms.
b-arrestins and Ubiquitination
More than just a regulatory mechanism for protein degradation,
the ubiquitin system controls complex cellular events such as
cell division, protein trafficking, and signal transduction, by addi-
tions of specific linkages of ubiquitin moieties to signaling
proteins (Mukhopadhyay and Riezman, 2007). Numerous recep-
tors and proteins important for proper development, including
b-catenin, Notch, and NF-kB, are subject to regulation by ubiq-
uitination. The TGFb and Hh pathways, as well as cell cycle
progression and apoptosis, are known to be tightly regulated
by ubiquitination. A functional role of b-arrestins in ubiquitination
was initially identified for the b2-adrenergic receptor (b2AR). The
b2AR is a prototypical GPCR that mediates multiple physiolog-
ical outcomes such as increased heart rate, vasodilation, and
pupillary dilation, among others. Stimulation of the b2AR leads
to Gs-dependent activation of adenylyl cyclase, an enzyme
that forms the second messenger cAMP. Desensitization of
b2ARs is conferred by GRK-dependent phosphorylation, fol-
lowed by the recruitment of b-arrestin. The RING ubiquitin
ligase Mdm2 catalyzes transient receptor-stimulated ubiquitina-
tion of b-arrestin 2, which is required for clathrin-mediated b2AR
internalization (Shenoy et al., 2001). Ubiquitinated b-arrestin
recruits certain endocytic components, such as clathrin and
AP-2, leading to rapid receptor internalization; however, the
mechanisms by which ubiquitination of b-arrestin enhances
b-arrestin/clathrin-dependent endocytosis remain to be eluci-
dated (Shenoy, 2007).
Interestingly, ubiquitinated b-arrestin has a higher affinity than
nonubiquitinated b-arrestin for many receptors and downstream
signaling intermediates, such as ERK (Shenoy et al., 2007).
Subsequent deubiquitination of b-arrestin 2 by the deubiquiti-
nase USP33 dissociates the receptor-b-arrestin complex (She-
noy et al., 2009). The internalized 7TMR is either degraded in
the lysosomal compartment or resensitized by dephosphoryla-
tion and recycled to the plasma membrane. These trafficking
processes are orchestrated by b-arrestins, which can recruit
either the HECT ubiquitin ligase neural precursor cell expressed,
developmentally downregulated 4 (Nedd4) for receptor degrada-
tion (Shenoy et al., 2008), or the deubiquitinases USP33 and
USP20 for b-arrestin deubiquitination and receptor recycling
(Berthouze et al., 2009). In other contexts, b-arrestin 2 appears
to recruit unknown ubiquitin ligases to the Gs-coupled Vaso-
pressin V2 Receptor (V2R), facilitating its ubiquitination and
degradation (Martin et al., 2003). b-arrestin 1 associates with
the HECT ubiquitin ligase atrophin-interacting protein 4 (AIP4)
to downregulate the Gi/o-coupled chemokine receptor CXCR4
(Bhandari et al., 2007).Developmental Cell 17, October 20, 2009 ª2009 Elsevier Inc. 451
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adaptors for diverse groups of E3 ubiquitin ligases (Table 3) to
facilitate ubiquitination of their substrates (Shenoy, 2007). We
have already mentioned this idea in the context of Mdm2 regula-
tion of the IGF1R (Girnita et al., 2005) and of Notch regulation by
Dx and Krz (Mukherjee et al., 2005). Cytosolic molecules are also
targeted for ubiquitination in a b-arrestin-dependent manner (Li
et al., 2009; Salcedo et al., 2006). Furthermore, recent studies
in yeast have shown that arrestin-related trafficking adaptors
(ARTs) regulate turnover of plasma membrane proteins, such
as the arginine transporter Can1 and the lysine transporter
Lyp1 (Lin et al., 2008). Despite lacking sequence homology
with b-arrestins, ARTs contain a short amino acid motif, the ‘‘ar-
restin motif,’’ within the predicted arrestin fold that is conserved
in the mammalian arrestin family and interacts with the HECT E3
ligase Rsp5 (a homolog of Nedd4 family proteins). Through this
interaction, ARTs lead to internalization and degradation of
amino acid transporters in an ubiquitination-dependent manner
(Lin et al., 2008). These findings suggest that arrestins are
bona fide ubiquitin ligase adaptors, and that this characteristic
of arrestins is remarkably conserved even among distantly
related proteins (i.e., ARTs) in species as divergent as yeast
and mammals.
The MAP Kinases
Many extracellular growth factors and stresses converge on the
MAPKs to control cellular proliferation, survival, and differentia-
tion. It is acutely important for the strength and kinetics of these
signals that they be tightly regulated. While classical G protein-
dependent ERK activation is rapid and transient, recent studies
demonstrate that b-arrestins produce a slower, but more persis-
tent response, perhaps allowing intricate regulation.
ERK. The ERK MAPK is the archetype for b-arrestin-mediated
signaling. Following agonist stimulation, GPCRs activate MAPK
through both Ga and Gbg subunit-dependent mechanisms
(Luttrell and Luttrell, 2003). This activated MAPK signal is rapid
and transient because it is quickly quenched by b-arrestin-medi-
ated desensitization of the receptor (Figure 5A). In a discrete yet
related process, b-arrestins scaffold the MAP kinase signaling
molecules, MAP kinase kinase kinase (Raf-1), MAP kinase
kinase (MEK1), and MAP kinase (ERK), leading to phosphoryla-
tion and activation of ERK 1/2 (DeWire et al., 2007) (Figure 5B).
G protein-mediated ERK activation is generally rapid but
transient, leading primarily to nuclear signaling via activation of
transcription factors. In contrast, b-arrestin-mediated ERK
responses are slower and more persistent, generally retaining
the activated kinases in the cytosol. This not only prevents
Table 3. E3 Ubiquitin Ligases Scaffolded by b-arrestins
E3 ubiquitin ligase Type Targets Reference
AIP4 HECT CXCR4 Bhandari et al., 2007
Deltex RING Notch Mukherjee et al., 2005
Mdm2 RING IGF1R,
Androgen
Receptor,
PDE4D5,
GRK-2, b2AR
Girnita et al., 2005;
Lakshmikanthan et al.,
2009; Salcedo et al.,
2006; Shenoy
et al., 2001
NEDD4 HECT b2AR Shenoy et al., 2008452 Developmental Cell 17, October 20, 2009 ª2009 Elsevier Inc.ERK from phosphorylating nuclear substrates, but results in
increased phosphorylation of cytosolic substrates, prolonging
signaling events (Figure 5B). This intricate balance between G
protein-dependent and b-arrestin-dependent ERK activation
regulates the strength, kinetics, and localization of the ERK/
MAPK signaling cascade.
An association with b-arrestin-dependent ERK activation has
been described for many 7TMRs including the angiotensin II
type 1A receptor (AT1AR) and b-adrenergic receptors (Table 1),
among others (DeWire et al., 2007). The physiological implica-
tions of b-arrestin-dependent ERK activation have recently
begun to come into focus. For example, in primary vascular
smooth muscle cells the AT1AR-b-arrestin-ERK signaling
complex uses distinct effectors to block apoptosis via BAD
phosphorylation (Ahn et al., 2009), stimulate translation through
Mnk1 phosphorylation of the translation initiation factor eIF4E
(DeWire et al., 2008), and trigger S-phase entry and cell prolifer-
ation with EGFR (Kim et al., 2009). These latter mitogenic
responses are very common among receptors that activate
ERK during b-arrestin-mediated endocytosis (Lin et al., 1998).
Thus, b-arrestin-dependent ERK activation regulates several
events that are important for the intricate regulation of develop-
mental processes.
JNK Family. JNK3 is another of the many MAPKs activated by
b-arrestin signaling pathways. The JNK family of protein kinases
(stress-activated protein kinases) phosphorylate Jun-family
components of the AP-1 transcription factor complex, thus
increasing AP-1 transcriptional activity (Davis, 2000). b-arrestin
2 acts as a scaffold for JNK3 and its upstream kinases ASK1
and MKK4 (McDonald et al., 2000). Stimulation of the AT1AR
leads to the formation of this b-arrestin 2-scaffold complex on
endosomal structures containing AT1AR, resulting in phosphory-
lated, active JNK3 accumulation in the cytosol (McDonald et al.,
2000), much like the ERK cascade discussed above. However, it
is still unknown which substrates are targeted by b-arrestin
2-activated JNK3 in the cytosol. This question is of considerable
interest, as JNK3 is strongly implicated in AP-1-dependent
neurotoxicity. Mice lacking JNK3 exhibit reduction in both
seizure activity and hippocampal neuron apoptosis in the kai-
nate-induced stroke model (Yang et al., 1997). Since b-arrestin
2 is also highly expressed in the hippocampus, it seems likely
that this activity is b-arrestin 2-dependent.
p38. b-arrestin-mediated signaling also leads to p38 phos-
phorylation and activation (Bruchas et al., 2006; Gong et al.,
2008; Miller et al., 2003; Sun et al., 2002), though it has not
directly been shown that b-arrestins scaffold either p38 or its
upstream kinases. Substrates of p38 include transcription
factors, such as p53 or activating transcription factor 2 (ATF2),
and protein kinases, including MAPK-activated kinase 2 (MK2)
and Mnk1. Activation of p38a is normally associated with inhibi-
tion of cell cycle progression both at the G1/S and G2/M transi-
tions, leading to antiproliferative effects (Wagner and Nebreda,
2009). So far, the principal contexts in which b-arrestin seems
to regulate p38 activation are after receptor stimulation. For
example, stimulation of b2AR causes phosphorylation and acti-
vation of p38, which is attenuated by b-arrestin1 RNAi (Gong
et al., 2008), and the b-arrestin-dependent chemotactic
response to stimulation of the chemokine receptor CXCR4 is
prevented by pharmacological p38 inhibitors (Sun et al., 2002).
Developmental Cell
ReviewDifferential Regulation of Akt by b-arrestins
Depending on the type of stimuli and the relevant receptors, b-
arrestins can scaffold different sets of molecules that determine
distinct, even opposite effects on the same signaling cascade.
One such example is Akt signaling, which is either activated or
suppressed by b-arrestin-recruited c-Src or protein phospha-
tase 2A (PP2A), respectively (Figures 5C and 5D).
Figure 5. b-arrestins Act as Signaling
Scaffolds
(A) GPCRs generate rapid and transient ERK,
which is attenuated by b-arrestins. (1) As ligand
(red circle) binds to the extracellular domain of
a GPCR, G proteins are activated (2) and generate
second messengers such as cAMP and DAG,
while (3) also stimulating the rapid and transient
phosphorylation of ERK. (4) This ‘‘G protein-stimu-
lated’’ ERK translocates into the nucleus and
modulates transcription. Meanwhile, (5) GRKs
phosphorylate the C-terminal tail of receptors,
thus (6) recruiting b-arrestins that sterically inhibit
G protein binding, thus attenuating generation of
second messengers. (7) b-arrestins also assist in
the internalization of receptors, thus leading to
their downregulation.
(B) b-arrestins act as signaling adaptors and acti-
vate cytosolic ERK in a persistent fashion. (1)
Upon ligand binding, (2) b-arrestins are recruited
to the receptor and (3) block G protein-mediated
signaling. (4) b-arrestins are able to stimulate the
phosphorylation of ERK, which leads to a slowly
developing, persistent pool of ‘‘b-arrestin-stimu-
lated’’ ERK that resides exclusively in the cytosol
and phosphorylates cytoplasmic substrates such
as (5) Mnk and p90Rsk. (6) b-arrestins are also
able to stimulate proteins such as c-Src and (7)
RhoA, leading to a wide range of responses.
(C) b-arrestin positively regulates Akt in response
to Insulin Receptor Stimulation. (1) Bindng of
Insulin (Ins) to the Insulin Receptor (IR) triggers
the binding of b-arrestin 2 to the receptor. (2) b-ar-
restin scaffolds c-Src to Akt, causing the phos-
phorylation of Akt by c-Src. (3) This phosphoryla-
tion allows PDK1 and PDK2 phosphorylation
events that (4) inhibit GSK3b.
(D) b-arrestins negatively regulate Akt in response
to Dopamine Receptor Stimulation. (1) Upon
binding of Dopamine (purple circle) to the D2
Dopamine Receptor, (2) G proteins inhibit cAMP
generation and (3) b-arrestin is recruited to the
receptor to relieve this repression. (4) Not only
does b-arrestin block further G protein-mediated
signaling, it also scaffolds PP2A to Akt, (5) thus
leading to the dephosphorylation of Akt, and the
generation of an inactive Akt (iAkt). (6) This leads
to the activation of GSK3b.
A physiological role forb-arrestin-medi-
ated c-Src recruitment and its effects on
Akt signaling was recently identified
(Luan et al., 2009). In canonical insulin-
mediated Akt activation, stimulation of
the insulin receptor, an RTK, ultimately
leads to the generation of phosphatidyli-
nositol (3,4,5) trisphosphate (PIP3). PIP3
binds to the pleckstrin homology (PH)
domain of Akt and phosphoinositide-
dependent kinases (PDKs), which then
phosphorylate and activate proximal Akt on the membrane.
Recently, it was revealed that b-arrestin 2 regulates insulin action
by scaffolding a complex-containing insulin receptor, c-Src, and
Akt (Luan et al., 2009). This complex allows c-Src to phosphory-
late Akt on Tyr 315 and Tyr 326, which are required for the
subsequent phosphorylation of Akt at Thr 308 and Ser 473 by
PDK1andPDK2, respectively (Figure 5C). Accordingly,b-arrestinDevelopmental Cell 17, October 20, 2009 ª2009 Elsevier Inc. 453
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b-arrestin 2 in mice causes increased insulin sensitivity (Luan
et al., 2009).
On the other hand, b-arrestin 2 can deactivate Akt by the
formation of a b-arrestin 2/PP2A/Akt complex upon stimulation
of the D2-class dopamine receptors (Beaulieu et al., 2005).
PP2A dephosphorylates Akt, blocking Akt function (Figure 5D).
Akt inactivation releases GSK3b from repressive phosphoryla-
tion by Akt, resulting in GSK3b activation. Lithium is a GSK3b
inhibitor (Klein and Melton, 1996) commonly used for the clinical
management of psychiatric diseases such as schizophrenia and
bipolar disorder; however, lithium may exert its therapeutic
actions via diverse mechanisms (Beaulieu et al., 2004). Interest-
ingly, lithium was recently shown to disrupt the signaling
complex of Akt, b-arrestin 2, and PP2A, promoting Akt activity
and greater inhibition of GSK3b (Beaulieu et al., 2008). Accord-
ingly lithium action on behavior is abrogated in b-arrestin 2
knockout mice where GSK3b is not inhibited (Beaulieu et al.,
2008).
These studies provide examples of how b-arrestins can affect
two different outcomes in the same signaling cascade (e.g., Akt),
dependent on the type of ligand and its relevant receptor. These
differing combinations of ligand-receptor interactions determine
which b-arrestins are recruited and which protein complexes are
scaffolded by b-arrestins. Moreover, such differential regulation
by b-arrestins is implicated in human disorders such as type II
diabetes and psychiatric disorders (Beaulieu et al., 2005; Luan
et al., 2009). Pharmacological manipulation of selective b-ar-
restin-dependent complexes (e.g., by lithium) may provide novel
therapeutic benefits in such disorders (Beaulieu et al., 2008).
Concluding Remarks
Recent studies have prompted a rapidly growing appreciation
of the roles of b-arrestins as both mediators of desensitization
and 7TMR signaling. In addition, it has become evident that
receptors from outside the 7TMR family, such as receptor
serine/threonine kinases, tyrosine kinases, and cytokine recep-
tors, also exploit b-arrestin-mediated scaffolding to regulate a
downstream signaling response. As b-arrestins continue to
emerge as broadly functioning adaptors for signaling molecules
such as protein kinases, ubiquitin ligases, and other signal
transducers, the roles that these versatile molecules play dur-
ing development will continue to expand and be defined. As
reviewed above, b-arrestins play critical roles in the precise
regulation of many signaling pathways, such as responses
to Hh, Wnts, and TGFbs. Future analyses of the diverse pheno-
types seen in Drosophila krzmutants, and in mouse tissues lack-
ing both b-arrestin 1 and 2, therefore represent a promising
approach to the discovery of new functions for nonvisual arrest-
ins in signaling and development.
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